These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

996 related items for PubMed ID: 28650001

  • 1. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L.
    Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
    [Abstract] [Full Text] [Related]

  • 2. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
    Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A.
    N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
    [Abstract] [Full Text] [Related]

  • 3. Brodalumab for the treatment of psoriasis.
    Galluzzo M, D'adamio S, Bianchi L, Talamonti M.
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1255-1271. PubMed ID: 27718760
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
    Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S.
    N Engl J Med; 2012 Mar 29; 366(13):1181-9. PubMed ID: 22455412
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
    Papp K, Leonardi C, Menter A, Thompson EH, Milmont CE, Kricorian G, Nirula A, Klekotka P.
    J Am Acad Dermatol; 2014 Dec 29; 71(6):1183-1190.e3. PubMed ID: 25313095
    [Abstract] [Full Text] [Related]

  • 10. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F, Li GG, Liu Q, Niu X, Li R, Ma H.
    J Immunol Res; 2019 Dec 29; 2019():2546161. PubMed ID: 31583255
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A, Desai SR, Qureshi A, Rastogi S, Alexis AF.
    Am J Clin Dermatol; 2019 Apr 29; 20(2):267-276. PubMed ID: 30471012
    [Abstract] [Full Text] [Related]

  • 12. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
    Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ.
    Br J Dermatol; 2018 Aug 29; 179(2):320-328. PubMed ID: 29488226
    [Abstract] [Full Text] [Related]

  • 13. Brodalumab: First Global Approval.
    Greig SL.
    Drugs; 2016 Sep 29; 76(14):1403-12. PubMed ID: 27577550
    [Abstract] [Full Text] [Related]

  • 14. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.
    J Dermatolog Treat; 2018 Sep 29; 29(6):569-578. PubMed ID: 29532693
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis.
    Galluzzo M, Talamonti M, D'adamio S, Bianchi L.
    Expert Opin Drug Metab Toxicol; 2017 Jun 29; 13(6):679-691. PubMed ID: 28460549
    [Abstract] [Full Text] [Related]

  • 16. Anti-IL17 therapies for psoriasis.
    Silfvast-Kaiser A, Paek SY, Menter A.
    Expert Opin Biol Ther; 2019 Jan 29; 19(1):45-54. PubMed ID: 30500317
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis.
    Umezawa Y, Nakagawa H, Niiro H, Ootaki K, Japanese Brodalumab Study Group.
    J Eur Acad Dermatol Venereol; 2016 Nov 29; 30(11):1957-1960. PubMed ID: 27358210
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
    Kivelevitch DN, Menter A.
    Immunotherapy; 2015 Nov 29; 7(4):323-33. PubMed ID: 25917624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.